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ABSTRACT
ObjectiveTocompare theeffectivenessandsafetyof three
types of stents (sirolimus eluting, paclitaxel eluting, and
bare metal) in people with and without diabetes mellitus.
Design Collaborative network meta-analysis.
Data sources Electronic databases (Medline, Embase, the
Cochrane Central Register of Controlled Trials), relevant
websites, reference lists, conference abstracts, reviews,
book chapters, andproceedings of advisory panels for the
US Food and Drug Administration. Manufacturers and
trialists provided additional data.
Review methods Network meta-analysis with a mixed
treatment comparison method to combine direct within
trial comparisons between stents with indirect evidence
fromother trialswhilemaintaining randomisation. Overall
mortality was the primary safety end point, target lesion
revascularisation the effectiveness end point.
Results35 trials in 3852peoplewith diabetes and 10947
people without diabetes contributed to the analyses.
Inconsistency of the network was substantial for overall
mortality in people with diabetes and seemed to be
related to thedurationofdualantiplatelet therapy (P value
for interaction 0.02). Restricting the analysis to trials with
a duration of dual antiplatelet therapy of six months or
more, inconsistency was reduced considerably and
hazard ratios for overall mortality were near one for all
comparisons in people with diabetes: sirolimus eluting
stents compared with bare metal stents 0.88 (95%
credibility interval 0.55 to 1.30), paclitaxel eluting stents
compared with bare metal stents 0.91 (0.60 to 1.38), and
sirolimus eluting stents compared with paclitaxel eluting
stents 0.95 (0.63 to 1.43). In people without diabetes,
hazard ratioswere unaffectedby the restriction. Both drug
eluting stents were associated with a decrease in
revascularisation rates compared with bare metal stents
in people both with and without diabetes.
Conclusion In trials that specified a duration of dual
antiplatelet therapy of six months or more after stent
implantation, drug eluting stents seemed safe and
effective in people both with and without diabetes.
INTRODUCTION
People with diabetes experience a more generalised
form of atherosclerosis than people without diabetes.
They are at an increased risk for coronary heart disease
and have more restenoses after the implantation of
coronary stents. On average sirolimus eluting stents
and paclitaxel eluting stents are associated with a
noticeable reduction in target lesion revascularisation
compared with bare metal stents, whereas the rates of
overall mortality and cardiacmortality associated with
the three stents are similar.1 Differences in the process
and dynamics of restenosis along with variations in
metabolic profiles may, however, alter safety or
effectiveness profiles of the different stent types,
particularly in people with diabetes.
Randomised trials have reported a reduced revascu-
larisation rate with both sirolimus eluting stents and
paclitaxel eluting stents compared with bare metal
stents in people with diabetes,2-4 w1-w3 but the trials were
hampered by small numbers of patients and a limited
duration of follow-up. A meta-analysis of four early
trials in 428 people with diabetes that compared
sirolimus eluting stents with bare metal stents for up
to four years suggested a strongly increased risk of
mortality (hazard ratio 2.90, 95% confidence interval
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1.38 to 6.10).5 In view of an average rate of overall
mortality of 12% over four years observed in people
with diabetes,1 this hazard ratio would translate into a
number needed to harm to cause one death over four
years as low as 4 (95% confidence interval 2 to 22).
Another meta-analysis, published simultaneously,6
also included more recent trials with shorter durations
of follow-up: pooling 14 trials in 1411 people with
diabetes resulted in a hazard ratio of only 1.27, but the
95% confidence interval ranged from 0.83 to 1.95 and
was compatible with both moderate benefit and
substantial harm.
Network meta-analyses7 8 or mixed treatment
comparisons9-11 allow a unified, coherent analysis of
all randomised controlled trials that comparedeither of
the two drug eluting stents with baremetal stents or the
two drug eluting stents head to head, while fully
respecting randomisation. In a previous networkmeta-
analysis1 we determined the average benefits and
harms of all three stent types and provided preliminary
results for overall mortality and the composite of death
or myocardial infarction stratified according to the
presence or absence of diabetes. Here we extend the
network meta-analysis stratified according to diabetes
status to include 35 trials in 14 799 patients, with data
from five additional trials,w4-w8 a longer follow-up in
one trial,w7 and data on cardiac death, myocardial
infarction, stent thrombosis, and target lesion revascu-
larisation as additional clinical outcomes.12 13 To
address earlier concerns5 we prespecified overall
mortality as the primary safety outcome and system-
atically explored the consistency of mortality data in
people with diabetes.
METHODS
We included randomised controlled trials in people
with symptoms or signs of myocardial ischaemia as a
result of coronaryarterydisease, that compared the two
first generation drug eluting stents approved by theUS
Food and Drug Administration, a paclitaxel eluting
stent (Taxus; Boston Scientific, Natick, MA) and a
sirolimus eluting stent (Cypher; Cordis, Miami Lakes,
FL) with each other or with a bare metal stent. Trials
had to have a clinical follow-up duration of at least six
months.
We searched Medline, Embase, the Cochrane
Central Register of Controlled Trials (from inception
of each database to October 2007), and relevant
websites (www.acc.org, www.tctmd.com, www.the
heart.org, www.clinicaltrialresults.org) for studies in
any language. We checked reference lists, conference
abstracts, relevant reviews, book chapters, and the
proceedingsof the relevant advisorypanels of theFood
and Drug Administration, and we contacted manufac-
turers and trialists. (Seewebextra appendix1 fordetails
of the search strategy.)
Data extraction
Two investigators (CSt, SA) extracted data indepen-
dently, with disagreements resolved in consultation
with a third investigator (PJ).We asked the trialists and
manufacturers of drug eluting stents to check the
extracted information and to provide additional out-
come data on an electronic form according to
standardised definitions and attempted to obtain out-
come data separately for people with and without
diabetes.
We specified overall mortality as the primary safety
outcome and target lesion revascularisation as the
primary effectiveness outcome. Target lesion revascu-
larisation was defined as repeat percutaneous inter-
vention of the target lesion or bypass surgery of the
target vessel done for restenosis or other complications
of the target lesion (ranging from 5 mm proximal to
5 mm distal to the stent). We recorded the following
secondary safety outcomes: cardiac death, defined as
any death due to a cardiac cause (for example,
myocardial infarction, low output failure, fatal arrhyth-
mia), procedure related deaths, deaths related to
concomitant treatment, and death of unknown cause;
myocardial infarction, including fatal and non-fatal
non-Q wave or Q wave myocardial infarction; a
composite of death or myocardial infarction; and
stent thrombosis, within the stented segment, con-
firmedby angiographyor post-mortemexamination in
accordance with the criteria of the Academic Research
Consortium, to ensure the inclusion of “secondary”
stent thrombosis occurring after a patient had under-
gone a target lesion revascularisation. In addition, we
recorded stent thrombosis according to the definitions
used in individual trials (per protocol definition). The
numbers of patients experiencing an event and the
overall number of patients at risk were recorded
separately for years 1 to 4.
To tackle potential sources of inconsistency in the
network we determined the month of completion of
patient recruitment as a measure of the period when a
trial was done, the duration of follow-up in years, and
theduration inmonths of dual antiplatelet therapyafter
stent implantation and assessed three key domains of
internal validity14: concealment of allocation, blinding
of research staff adjudicating clinical outcomes, and the
inclusion of all randomised participants in the analysis
according to the intention to treat principle. We
considered trials to be of high quality that satisfied all
three criteria (see also the criteria forquality assessment
in the web extra, appendix 1). Inmost trials the precise
durations of dual antiplatelet therapy in individual
patients were unavailable. Therefore we obtained all
relevant auxiliary informationavailable for trialswith a
duration of dual antiplatelet therapy of less than six
months, such as the information stated in the protocol
and the percentage of patients reporting the use of dual
antiplatelet therapy at relevant time points. On the
basis of this information two investigators (CSt, PJ)
independently classified trials according to the likely
percentageof patients taking clopidogrel at sixmonths,
in increments of 10% (<10%, 10% to <20%, and so on).
Statistical analysis
We used a hierarchical random effects model15 for
mixed treatment comparisons9 based on piecewise
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constant hazards, with random effects at the levels of
trials, adjacent time periods, and comparisons. We
simultaneously estimated log hazard ratios for people
with and without diabetes and the difference in log
hazard ratios between such people. From the posterior
distribution of the difference we estimated the P values
for interaction between treatment effect and diabetes
status. We excluded from the analyses time periods
with zero events in both groups. Hazard ratios were
estimated from the median, and the accompanying
95% credibility intervals from the 2.5th and 97.5th
centiles of the posterior distribution. Because of low
event rates we derived relative risks of stent throm-
boses using a previously described random effects
Poisson regressionmodel.11As in the preceding study,1
we did separate analyses according to time of
occurrence of stent thrombosis and an analysis of per
protocol definitions of stent thrombosis as used in
individual trials (seeweb extra appendix 1 for details of
the models).
We evaluated the inconsistency of the network,
defined as the variability of results across different
comparisons of the network, by calculating inconsis-
tency factors: the estimated difference between the log
hazard ratios from direct comparisons within rando-
mised trials and the log hazard ratios from indirect
comparisons between randomised trials with one
intervention in common.1 To allow intuitive inter-
pretationwe back transformed absolute values of these
inconsistency factors to ratios of hazard ratios and
expressed inconsistency as percentage difference in
hazard ratios between direct randomised comparisons
within trials and indirect comparisons between trials.
Values can range from 0% to infinity. A value near 0
indicates that all the comparisons in the network are
consistent, showing fully coherent estimates of hazard
ratios comparing any two types of stent. The more the
value deviates from 0% the more inconsistent the
network. A value of 25%, corresponding to a ratio of
hazard ratiosof 1.25,maybe interpreted to indicate low
inconsistency, a value of 50%moderate inconsistency,
and a value of 100%, corresponding to a ratio of hazard
ratios of 2.00, high inconsistency (see web extra
appendix 1). We evaluated heterogeneity between
trials, definedasvariabilityof results across trialswithin
comparisons over and above chance, and the goodness
of fit of the model to the data (see web extra appendix
1).
To investigate potential sources of variation in the
network, we included the characteristics of the trials as
covariates in the network meta-analysis of the primary
safety outcome. We used prespecified cut-off points of
two years for the length of follow-up, January 2004 for
completion of patient recruitment, and six months for
the duration of dual antiplatelet therapy. In some
instances the numbers of trials and events were too low
to allow the estimation of random effects at the level of
time periods. Therefore we used a random effects
Poisson regression model (see web extra appendix 1)
for all of these analyses.11 P values for interaction
between trial characteristics and treatment effect were
derived from the posterior distribution of covariates.
The duration of dual antiplatelet therapy specified in
trial protocolswas theonlyvariablewith a treatmentby
trial characteristic interaction at P<0.05. Therefore we
restricted the dataset to trials with a duration of dual
antiplatelet therapy of six months or longer and
repeated all analyses. Heterogeneity between trials,
defined as variability of results across trials within
comparisons over and above chance, and the goodness
of fit of the model to the data, were evaluated as
previously reported (see web extra appendix 1).1 All
analyses were done in WinBUGS version 1.4.1 and
Stata version 9.2.
RESULTS
Forty two trialsw1-w42 met the inclusion criteria (fig 1).
Seven trials, totalling about 900 people with diabetes
and 3000 without, were excluded because data
stratified by diabetes status were not obtainable.w15
w34 w36 w37 w39 w41 w42 The remaining 35 trialsw1-w14 w16-w33
w35 w38 w40 were included. Investigators or manufac-
turers provided additional data for 32 trials.w1 w4-w14 w16-
w19 w21-w33 w35 w38 w40 (The characteristics of the 35
included trials are presented in web extra table A.)
Four trialsw1-w3 w29 included only people with diabetes
andone trial onlypeoplewithout diabetes.w33 The trials
had randomly allocated 3852 people with diabetes
mellitus and 10 947 people without diabetes mellitus.
Patient recruitment started between August 2000w16
and October 2004w4 and was completed between
January 2001w16 andNovember 2005.w5 Data stratified
according to the presence or absence of diabetes were
available for all 35 trials on all outcomes, except stent
thrombosis (seewebextra tablesBandC).Twentynine
trials described appropriate methods for allocation
concealment,w1 w2 w7 w8 w11-w14 w16-w33 w35 w38 w40 and 28
trials reported blind adjudication for clinical out-
comes.w1 w4 w7 w9-w14 w16-w26 w28-w30 w32 w33 w35 w38 w40 For 30
trials all randomised patients could be included in the
analyses according to the intention to treat principle.w1
w3-w7 w9 w11 w13 w14 w16-w23 w25-w33 w35 w38 w40 Twenty four
trials were considered to be of high quality.w1 w7 w11 w13
w14 w16-w23 w25 w26 w28-w30 w32 w33 w35 w38 w40
Duration of dual antiplatelet therapy
The duration of dual antiplatelet therapy specified in
the study protocols was twomonths in five trials,w16 w18-
w20 w26 threemonths in three,w3 w7 w17 sixmonths in 18,w2
w5 w9-w14 w21 w22 w24 w28 w29 w32 w33 w35 w38 w40 nine months in
one,w4 and 12 months in eight.w1 w6 w8 w23 w25 w27 w30 w31
All eight trials with therapy lasting less than sixmonths
compared sirolimus eluting stents with bare metal
stents. Auxiliary information for these trials (see web
extra appendix 2) indicated that the percentage of
patients actually receiving dual antiplatelet therapy of
six months or more was likely to be below 10% in five
trials.w7 w16-w19 The likely percentage for the other three
trials was between 10% and 20%,w20 40% and 50%,w26
and50%and60%.w3Onehead to head comparisonhad
specified a minimal duration of dual antiplatelet
therapy of two months for sirolimus eluting stents
RESEARCH
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and six months for paclitaxel eluting stents in the
protocol, but the actual duration was only one month
shorter for patients allocated to siroliumus stents than
for patients allocated to paclitaxel stents, and about
50% of patients allocated to either stent type were still
receiving therapy after eight months.w32
Network of all trials: overall mortality
Table 1 presents the results of the network meta-
analysis of overallmortality in peoplewith andwithout
diabetes. In people with diabetes the estimated hazard
ratio for sirolimus eluting compared with bare metal
stents was 1.14 (95% credibility interval 0.74 to 1.60),
for paclitaxel eluting versus bare metal stents was 1.09
(0.71 to 1.66), and for sirolimus versus paclitaxel
eluting stents was 1.02 (0.70 to 1.57), and compatible
with both a substantial harm and amoderate benefit of
either eluting stent compared with bare metal stents.
The corresponding values for people without diabetes
were 1.02 (0.77 to 1.29), 0.90 (0.67 to 1.16), and 1.13
(0.83 to 1.54; table 1). A moderate to high incon-
sistencyof 61%was found amongpeoplewithdiabetes,
but none among people without diabetes.
Exploration of sources of variation
Table 2presents an investigation intopotential sources
of variation in people with diabetes in the network.
Estimates of relative risk comparing sirolimus eluting
stents with paclitaxel eluting stents depended to some
extent on the quality of the trials, the length of follow-
up, and the time of completion of patient recruitment
(table 2), but 95% credibility intervals were wide and
tests for interaction negative (P for interaction ≥0.16).
The estimated relative risk of death when sirolimus
eluting stents were compared with bare metal stents
was greater when the specified duration of dual
antiplatelet therapy was less than six months (2.37,
95%credibility interval 1.18 to5.12) comparedwith six
months or longer (0.89, 0.58 to 1.40, P for interaction
0.02), however. When three trials originally classified
to have a short duration of dual antiplatelet therapyw3
w20 w26 were reclassified to have a durationof sixmonths
or longer, reflecting the auxiliary information indicat-
ing that more than 10% of patients in these trials were
still receiving dual antiplatelet therapy at six months,
differences were maintained.
Restricted network: overall mortality
When the network was restricted to trials with dual
antiplatelet therapy for six months or longer (table 1),
the hazard ratios of death overall among people with
diabetes were all below 1: sirolimus eluting stents
compared with bare metal stents 0.88 (95% credibility
interval 0.55 to 1.30), paclitaxel eluting stents com-
pared with bare metal stents 0.91 (0.60 to 1.38), and
sirolimus eluting compared with paclitaxel eluting
stents 0.95 (0.63 to 1.43). Compared with the network
of all trials the inconsistency decreased to 20% and
credibility intervals of hazard ratios became more
narrow in the restricted network. Among patients
without diabetes results were much the same in the
overall and the restrictednetwork (table 1). Thehazard
ratio for sirolimus eluting stents compared with bare
metal stents was 1.05 (0.69 to 1.73), for paclitaxel
eluting stents compared with bare metal stents it was
0.89 (0.66 to 1.18), and for sirolimus compared with
paclitaxel eluting stents itwas1.23 (0.82 to1.69). Figure
2 presents corresponding cumulative incidences of
death for the three stent types estimated from the
restricted network meta-analysis separately for people
with and without diabetes. The incidence of death was
about twice as high in people with diabetes compared
with people without diabetes. Tests for interaction
between treatment effect and diabetes status were
negative for all comparisons (P for interaction ≥0.28;
also see web extra table D).
Restricted network: secondary safety outcomes
Table 1 allows a comparison of the results from the
network meta-analysis of all trials and the analysis
restricted to trials with a dual antiplatelet therapy of six
months or more. Among people with diabetes, hazard
ratios for drug eluting stents comparedwith baremetal
stents became more beneficial for drug eluting stents
for the outcomes of cardiac death, the composite of
death or myocardial infarction, and for stent throm-
boses. The inconsistency decreased mainly for cardiac
death and per protocol definitions of stent thromboses.
No differences between overall and restricted network
meta-analysiswereobserved formyocardial infarction.
Among people without diabetes, results from overall
and restricted network meta-analysis were similar.
Corresponding cumulative incidences for the three
Reports excluded (n=786):
  Different interventions (n=424)
  Reviews or pooled analyses (n=254)
  Observational studies (n=98)
  Case reports (n=10)
Reports excluded (n=2):
  Different interventions (n=2, 1 trial)
Reports carefully examined (n=86, 42 trials):
  Trials of paclitaxel eluting versus bare metal stents (n=9)
  Trials of sirolimus eluting  versus bare metal stents (n=17)
  Trials of paclitaxel eluting versus sirolimus eluting stents (n=14)
  Trials of paclitaxel eluting versus sirolimus eluting stents
    versus bare metal stents (n=2)
Reports included (n=79, 35 trials):
  Trials of paclitaxel eluting versus bare metal stents (n=8)
  Trials of sirolimus eluting  versus bare metal stents (n=16)
  Trials of paclitaxel eluting versus sirolimus eluting stents (n=10)
  Trials of paclitaxel eluting versus sirolimus eluting stents
    versus bare metal stents (n=1)
Reports excluded (n=7):
  No separate data available on people
    with and without diabetes (n=7, 7 trials)
Potentially eligible reports identified
and screened for retrieval (n=874)
Reports retrieved for detailed evaluation (n=88, 45 trials)
Fig 1 | Identification of trials
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stent types are presented in figures 2 and 3. Again,
incidences were higher in people with diabetes than
without, with most pronounced differences observed
for cardiac death. Tests for interaction between
treatment effect and diabetes status were negative for
all comparisons on cardiac death, myocardial infarc-
tion, and their composite (P for interaction ≥0.47, see
also web extra table D).
Table 3 presents a breakdown of stent thromboses
according to time of occurrence. Among people with
diabetes little evidence was found for an increased risk
of definite or per protocol stent thrombosis associated
with sirolimus eluting stents compared with either of
the two other stents; all point estimates were below 1
and differences in favour of sirolimus eluting stents
becamemore pronounced with the use of per protocol
definitions. For the comparison of paclitaxel eluting
stents with bare metal stents all estimates were
imprecise for both the Academic Research
Consortium definition of definite stent thrombosis
and per protocol definitions. Among people without
diabetes relative risks were generally higher for both
definitions, but tests for interaction between treatment
effect and diabetes status were positive only for the
comparison of sirolimus eluting stents with bare metal
stents on per protocol definitions of stent thrombosis
between day 0 and 4 years and between day 30 and
4 years (P for interaction=0.01, see also web extra table
D).
Restricted network: target lesion revascularisation
Bothdrug eluting stentswere robustly associatedwith a
decrease in revascularisation rates comparedwith bare
metal stents, network inconsistency was low, and
results were unaffected by the restriction of the analysis
to trials with a duration of dual antiplatelet therapy of
sixmonthsormore inpeoplewith andwithoutdiabetes
(table 1). Differences between sirolimus and paclitaxel
Table 1 | Analyses overall and restricted to trialswith dual antiplatelet therapy of at least sixmonths
Variable and stent types
People with diabetes People without diabetes
All trials
Trials with dual antiplatelet
therapy ≥6 months All trials
Trials with dual antiplatelet
therapy ≥6 months
Hazard ratio (95% CI) IC* Hazard ratio (95% CI) IC* Hazard ratio (95% CI) IC* Hazard ratio (95% CI) IC*
Death overall:
SES v bare metal stent 1.14 (0.74 to 1.60)
61%
0.88 (0.55 to 1.30)
20%
1.02 (0.77 to 1.29)
3%
1.05 (0.69 to 1.73)
1%PES v bare metal stent 1.09 (0.71 to 1.66) 0.91 (0.60 to 1.38) 0.90 (0.67 to 1.16) 0.89 (0.66 to 1.18)
SES v PES 1.02 (0.70 to 1.57) 0.95 (0.63 to 1.43) 1.13 (0.83 to 1.54) 1.23 (0.82 to 1.69)
Cardiac death:
SES v bare metal stent 1.09 (0.63 to 1.93)
24%
0.80 (0.42 to 1.57)
4%
0.88 (0.48 to 1.60)
10%
0.93 (0.45 to 1.81)
12%PES v bare metal stent 1.08 (0.62 to 2.28) 0.94 (0.52 to 1.87) 0.90 (0.52 to 1.54) 0.89 (0.55 to 1.47)
SES v PES 0.98 (0.46 to 2.08) 0.85 (0.50 to 1.55) 0.96 (0.58 to 1.84) 1.04 (0.54 to 1.95)
Myocardial infarction:
SES v bare metal stent 0.68 (0.44 to 1.05)
30%
0.68 (0.43 to 1.12)
30%
0.87 (0.64 to 1.20)
5%
0.81 (0.55 to 1.14)
20%PES v bare metal stent 0.84 (0.55 to 1.31) 0.85 (0.54 to 1.43) 1.08 (0.74 to 1.51) 1.05 (0.72 to 1.42)
SES v PES 0.79 (0.56 to 1.23) 0.80 (0.55 to 1.27) 0.81 (0.58 to 1.06) 0.75 (0.57 to 1.07)
Death or myocardial
infarction:
SES v bare metal stent 1.04 (0.75 to 1.61)
57%
0.88 (0.57 to 1.27)
56%
0.93 (0.71 to 1.13)
6%
0.91 (0.69 to 1.13)
13%PES v bare metal stent 1.07 (0.74 to 1.62) 0.91 (0.70 to 1.31) 1.04 (0.84 to 1.31) 1.00 (0.84 to 1.25)
SES v PES 0.97 (0.72 to 1.34) 0.95 (0.69 to 1.27) 0.90 (0.71 to 1.09) 0.88 (0.71 to 1.06)
Stent thrombosis (ARC
definite):
SES v bare metal stent 0.46 (0.15 to 1.42)
26%
0.33 (0.09 to 1.09)
24%
1.35 (0.76 to 2.73)
32%
1.24 (0.58 to 3.08)
20%PES v bare metal stent 1.05 (0.32 to 4.01) 0.82 (0.23 to 3.09) 1.54 (0.83 to 3.13) 1.48 (0.69 to 3.40)
SES v PES 0.44 (0.15 to 1.17) 0.40 (0.13 to 1.08) 0.87 (0.47 to 1.69) 0.84 (0.41 to 1.88)
Stent thrombosis (per
protocol):
SES v bare metal stent 0.48 (0.17 to 1.35)
20%
0.20 (0.05 to 0.68)
5%
1.43 (0.78 to 3.00)
8%
1.48 (0.74 to 3.41)
10%PES v bare metal stent 1.27 (0.38 to 4.91) 0.73 (0.19 to 2.80) 1.73 (0.88 to 3.61) 1.80 (0.89 to 3.67)
SES v PES 0.38 (0.11 to 1.07) 0.27 (0.07 to 0.80) 0.82 (0.44 to 1.73) 0.82 (0.44 to 1.73)
Target lesion
revascularisation:
SES v bare metal stent 0.29 (0.22 to 0.39)
2%
0.29 (0.19 to 0.45)
0%
0.29 (0.22 to 0.38)
3%
0.29 (0.19 to 0.42)
1%PES v bare metal stent 0.38 (0.28 to 0.55) 0.38 (0.26 to 0.56) 0.46 (0.33 to 0.60) 0.46 (0.32 to 0.60)
SES v PES 0.76 (0.53 to 1.05) 0.78 (0.50 to 1.14) 0.63 (0.49 to 0.82) 0.64 (0.49 to 0.84)
SES=sirolimus eluting stent; PES=paclitaxel eluting stent; ARC=Academic Research Consortium.
*Inconsistency of network expressed as percentage difference in hazard ratios between direct randomised comparisons within trials and indirect comparisons between trials. Values near 0
indicate that all comparisons in network are consistent, showing fully coherent estimates of hazard ratios comparing any two stent types. Values can range from 0% to infinity. The more
values deviate from 0%, the more inconsistent the network. A value of 25% may be interpreted to indicate low inconsistency, 50% moderate, and 100% high inconsistency. (Also see table 5
in web extra appendix 3 for 95% credibility intervals and P values of inconsistency estimates.)
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eluting stents tended to be less pronounced among
people with diabetes, and the credibility intervals
overlapped 1 (fig 4). Tests of interaction between
treatment effect and diabetes status were negative (P
values for interaction≥0.44, see alsowebextra tableD).
Between trial heterogeneity, model fit, and comparison
with conventional meta-analyses
Web extra appendix 3 presents results from the
evaluations of heterogeneity between trials and
model fit. After restricting the network to trials with
dual antiplatelet therapy of six months or more,
heterogeneity between trials was low for all outcomes
except stent thrombosis. For people without diabetes
heterogeneity between trials was low for death, myo-
cardial infarction, and the composite of death or
myocardial infarction, andmoderate formost compar-
isons on the other three outcomes. The model fit was
adequate for all outcomes.Web extra tableEpresents a
comparison of results from network meta-analyses
with results from conventional meta-analyses: all
estimates were compatible.
DISCUSSION
Our collaborative network meta-analysis suggests that
previously reported increases in the risk of death
associated with sirolimus eluting stents compared with
bare metal stents in people with diabetes5 probably
resulted fromthe restricteddurationofdual antiplatelet
therapy of less than six months in early trials. In trials
with dual antiplatelet therapy for less than six months,
the risk of death associatedwith sirolimus eluting stents
wasmore than twice the risk associatedwith baremetal
stents, which translates into a number needed to harm
as low as 7 to cause one death over four years.
Conversely, trials with dual antiplatelet therapy for six
months or more showed no increase in risk from using
sirolimus eluting stents compared with bare metal
stents. Restricting the network to trials with dual
antiplatelet therapy of six months or longer resulted
in a clear reduction of the inconsistency and hazard
ratios near 1, which were robust to all sensitivity
analyses. We found similar patterns for analyses of
cardiac death and stent thromboses. The restriction of
the network resulted in a smaller evidence base: eight
trials of 613 people with diabetes were excluded from
the analysis. Despite this, statistical precision was
improved owing to the accompanying decrease in the
network’s inconsistency.
Compared with bare metal stents, target lesion
revascularisation rates are strongly decreased by use
of sirolimus and paclitaxel drug eluting stents in people
with and without diabetes. Numbers needed to treat to
reduce one event over four years are 6 in people with
diabetes and 8 in people without diabetes. Active
angiographic follow-up increases the absolute rates of
target lesion revascularisation.16 17 For example, the
rate of target lesion revascularisation at one year in
patients who had undergone implantation of a bare
metal stent in the TAXUS IV trial was 18.9% in those
allocated to active follow-up and 14.3% in those
allocated to regular clinical follow-up without
Table 2 | Overall mortality in patientswith diabetes: evaluation of variation in network according to different trial characteristics
Characteristic
SES v bare metal stent PES v bare metal stent SES v PES
Relative risk (95% CI) P value for interaction Relative risk (95% CI) P value for interaction Relative risk (95% CI) P value for interaction
Concealment of allocation:
Adequate 1.30 (0.86 to 2.02)
0.16
1.22 (0.74 to 1.99)
0.72
1.06 (0.69 to 1.67)
—
Unclear 0.32 (0.03 to 2.27) 0.93 (0.21 to 4.33) —
Blind adjudication:
Yes 1.30 (0.84 to 2.16)
0.37
1.17 (0.67 to 1.96)
0.96
1.11 (0.69 to 2.04)
0.78
No 0.72 (0.17 to 2.46) 1.24 (0.10 to 11.76 ) 0.94 (0.26 to 2.64)
Intention to treat analysis:
Yes 1.25 (0.81 to 2.02)
0.71
1.13 (0.65 to 1.92)
0.92
1.11 (0.71 to 1.87)
Not estimable*
No or unclear 0.97 (0.26 to 3.82) 1.08 (0.37 to 3.23) 0.14 (0.01 to 3.10)*
High quality trial:
Yes 1.40 (0.86 to 2.49)
0.27
1.28 (0.66 to 2.44)
0.61
1.08 (0.64 to 2.14)
0.80
No 0.70 (0.21 to 2.18) 0.97 (0.37 to 2.52) 0.93 (0.26 to 2.77)
Length of follow-up:
>2 years 1.37 (0.80 to 2.48)
0.51
1.30 (0.71 to 2.46)
0.54
1.05 (0.61 to 1.90)
0.97
≤2 years 1.01 (0.47 to 2.19) 0.91 (0.34 to 2.48) 1.02 (0.29 to 4.13)
Patient recruitment:
Completed Jan 2004 or later 0.93 (0.52 to 1.73)
0.93
1.11 (0.60 to 2.06)
0.54
0.83 (0.54 to 1.33)
0.94
Completed before Jan 2004 1.70 (0.96 to 3.08) 0.84 (0.41 to 1.81) 3.68 (0.41 to 32.9)*
Dual antiplatelet therapy:
≥6 months 0.89 (0.58 to 1.40)
0.02
0.97 (0.64 to 1.49)
—
0.92 (0.64 to 1.34)
—
<6 months 2.37 (1.18 to 5.12) — —
A random effects Poisson regression model was used to derive relative risks from network; estimates may therefore differ slightly from those reported in table 1 and figure 2. *Relative risks
for these comparisons are derived from one trial.
*Single trial had zero events in one arm.
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mandatory angiography. The number needed to treat
to avoid one revascularisation would therefore be
somewhat lower in clinical routine. Assuming revas-
cularisation rates of 12% in people with diabetes and
9% in people without diabetes, as found in the Cardiac
Care Network of Ontario at two years,18 numbers
needed to treat were estimated as 13 for people with
diabetes and 18 for people without diabetes.
Our study comprises a large body of evidence from
randomised controlled trials in people with and with-
out diabetes treated with one of two drug eluting stents
or bare metal stents. Investigators and manufacturers
provided additional data according to uniform out-
come definitions, including a standardised definition
for stent thrombosis according to the Academic
Research Consortium consensus.13 This increases
comparability between trials and limits bias, such as
the censoring of events after intervening revascularisa-
tion.
Our previous network meta-analysis1 was recently
criticised for integrating evidence from direct and
indirect comparisons, for not comparing like with like,
and for using random effects models that give undue
weight to small studies.19 Our model was based on
relative treatment effects (log hazards ratio), and
variations in characteristics of patients or lesions
between trials are fully accounted for in the analysis
by maintaining randomised comparisons within each
trial.1 Network meta-analysis makes similar assump-
tions to standard meta-analysis of direct comparisons
within trials, but requires that these assumptions hold
over the entire set of trials in the network.10 The smaller
the heterogeneity between trials and the smaller the
inconsistency of the data, the more likely relative
treatment effects originate from the same distribution
and less likely small trials get undue weight in the
analysis. Therefore a careful exploration of hetero-
geneity between trials and inconsistency of the data is
mandatory. Inspecting the entirenetwork allowedus to
gain insights into potential sources of variation, which
couldnot have been achievedby an isolated look at just
one setof trials comparingonly twostent types.This led
us to suggest a plausible explanation for the previously
reported increase in the risk of death associated with
sirolimus eluting stents compared with bare metal
stents in people with diabetes5—that is, a restricted
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Fig 2 | Cumulative incidence of death overall and cardiac death and corresponding hazard ratios (95%credibility intervals) for three
stent types estimated from network meta-analysis for pairwise comparisons in people with and without diabetes and restricted to
trials with dual antiplatelet therapy of at least six months
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duration of dual antiplatelet therapy particularly in
early trials.
Our exploration of inconsistency is observational in
nature and has the same limitations as other observa-
tional studies.20 Most importantly, earlier trials had
specified shorter durations of dual antiplatelet therapy
than later trials. The duration of therapy was therefore
bound to be negatively correlated with the duration of
follow-up, and confounding could exist between the
duration of therapy and the length of follow-up. Other
potential confounders include changes over time in
patient selectionandprocedural characteristics, suchas
an under-sizing or under-expansion of stents in early
trials, or methodological quality.We addressed this by
repeating tests of interaction between treatment effect
and components ofmethodological quality or length of
follow-up after the exclusion of trials with a duration of
dual antiplatelet therapy of less than six months and
found no evidence for an interaction in any of these
analyses (data available on request).
We acknowledge that our results could be corrobo-
rated by an analysis of the actual duration of dual
antiplatelet therapy in individual patients, but precise
durations in individual patients are unavailable inmost
trials and we lacked the resources to retrospectively
ascertain and validate usage data. Eight trials had
specified a duration of dual antiplatelet therapy of less
than sixmonths. For five trialswe are confident that the
actual duration of dual antiplatelet therapy corre-
sponded to the specified duration in at least 90% of
patientsw7 w16-w19; in three trials, however, between 10%
and 50%of the patients had dual antiplatelet therapy at
six months.w3 w20 w26 Results were unaffected by the
reclassificationof these three trials to have aduration of
dual antiplatelet therapy of six months or longer, and
thePvalue for interactionbetween relative riskof death
and duration of dual antiplatelet therapy became even
smaller. Additionally, strut thickness or type of bare
metal stent used in comparison groups might affect
clinical outcomes.w21 Even though our results are
robust to the adjustment for these characteristics of
bare metal stents,1 we cannot fully exclude the
possibility that differences in bare metal stents as
comparators contributed to the observed variation in
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and without diabetes and restricted to trials with dual antiplatelet therapy of at least six months
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mortality between trials with short and long durations
of dual antiplatelet therapy. Four trials included only
people with diabetesw1-w3 w29 and one trial only people
without diabetes.w33 Performing network meta-ana-
lyses separately for people with and without diabetes
allowed us to also incorporate these trials in our
analysis. An alternative approach would have been to
model differences between people with and without
diabetes directly within each trial, but at the price of
excluding these five trials.w1-w3 w29 w33 A final limitation
of our study is that we were unable to record
information on specific antidiabetic treatment or on
glycaemic control in people with diabetes mellitus and
to perform separate analyses for people with diabetes
who did or did not use insulin. Although these aspects
are related to cardiovascular outcomes,21 theywere per
Table 3 | Stent thromboses in trialswith dual antiplatelet therapy of sixmonths ormore
Variable
Events Relative risks (95% credibility interval)
BMS PES SES Total SES v BMS PES v BMS SES v PES
ARC definite stent thrombosis*
Patients with diabetes:
No of patients at risk 557 874 753 2184
0 days to 4 years 13 17 9 39 0.33 (0.09 to 1.09) 0.82 (0.23 to 3.09) 0.40 (0.13 to 1.08)
0-30 days 11 9 6 26 0.25 (0.04 to 1.11) 0.39 (0.05 to 2.36) 0.60 (0.12 to 3.36)
>30 days to 4 years 2 8 3 13 0.72 (0.04 to 10.8) 3.54 (0.23 to 78.6) 0.20 (0.02 to 1.04)
Patients without diabetes:
No of patients at risk 2439 3130 2647 8216
0 days to 4 years 34 56 46 136 1.24 (0.58 to 3.08) 1.48 (0.69 to 3.40) 0.84 (0.41 to 1.88)
0-30 days 19 22 28 69 1.19 (0.43 to 3.09) 1.11 (0.38 to 2.97) 1.06 (0.41 to 2.90)
>30 days to 4 years 15 34 18 67 1.19 (0.43 to 4.13) 1.83 (0.67 to 5.85) 0.65 (0.26 to 1.70)
Per protocol definition of stent thrombosis†
Patients with diabetes:
No of patients at risk 723 912 870 2505
0 days to 4 years 16 18 7 41 0.20 (0.05 to 0.68) 0.73 (0.19 to 2.80) 0.27 (0.07 to 0.80)
0-30 days 11 10 5 26 0.23 (0.03 to 1.08) 0.55 (0.09 to 3.05) 0.42 (0.07 to 1.89)
>30 days to 4 years 5 8 2 15 0.10 (0.01 to 0.93) 0.87 (0.06 to 10.3) 0.11 (0.01 to 0.75)
Patients without diabetes:
No of patients at risk 2577 3382 2625 8584
0 days to 4 years 29 58 46 133 1.48 (0.74 to 3.41) 1.80 (0.89 to 3.67) 0.82 (0.44 to 1.73)
0-30 days 22 24 28 74 1.11 (0.47 to 2.81) 0.99 (0.44 to 2.33) 1.15 (0.48 to 2.72)
>30 days to 4 years 7 34 18 59 2.29 (0.83 to 7.77) 4.12 (1.55 to 13.1) 0.55 (0.25 to 1.27)
BMS=bare metal stent; PES=paclitaxel eluting stent; SES=sirolimus eluting stent.
*According to Academic Research Consortium criteria.
†According to protocol definitions used in individual trials.
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definition randomly distributed across comparison
groups within each trial and it seems unlikely that they
influenced results.
We found that the duration of dual antiplatelet
therapy modified the safety profile of drug eluting
stents mainly in people with diabetes. The beneficial
effect of prolonged therapy in people with diabetes
may be mainly related to differences in lesion
characteristics. People with diabetes tend to have
smaller vessels and longer lesions than people without
diabetes and therefore require stents of smaller size and
longer length. Previous studies have identified both
vessel size and lesion length as predictors of stent
thrombosis,22 which may explain the predisposition of
people with diabetes to this adverse event in the
absence of adequate antiplatelet therapy. In necropsy
studies, drug eluting stents delayed arterial healing and
re-endothelialisation compared with bare metal
stents.23 24 Again, this effectmay be enhanced in people
with diabetes, particularly in the absence of dual
antiplatelet therapy. Moreover, overall longer stents
in people with diabetes may result in a prolongation of
the healing and re-endothelialisation process. Finally,
people with diabetes may bemore likely to experience
aspirin resistance than people without diabetes25 and
may have a particular benefit from a complementary
antiplatelet therapy with clopidogrel or ticlopidine.
Taken together, these mechanisms may explain why
prolonged dual antiplatelet therapy may be particu-
larly important in people with diabetes.
We recently reported a potentially reduced average
risk of myocardial infarction associated with sirolimus
eluting stents compared with bare metal stents but not
with paclitaxel eluting stents comparedwith baremetal
stents.1 Our analysis suggests that this effect is likely to
be present in people with diabetes, but wide credibility
intervals of stratified analyses preclude firm conclu-
sions. Stone et al found that about 1.4% of patients
undergoing target lesion revascularisation developed a
myocardial infarction associated with the procedure.26
A stent that decreases revascularisation rates will
therefore result in a reduction of procedure related
myocardial infarctions but this will result in a
maximum reduction of the relative risk of about 4%,
whereas the actually observed average relative risk
reduction was 19%.1 Other mechanisms will therefore
have tobeconsidered.Theprocessof restenosis in itself
may result in myocardial infarction in some patients,27
and a more pronounced reduction of restenosis of
sirolimus eluting stents may directly contribute to
decreasing the risk of myocardial infarction. Although
stent thrombosis is uncommon it is associated with a
high incidence of myocardial infarction,26 and the
benefits of drug eluting stents for myocardial infarc-
tions are less likely to be offset by stent thromboses in
sirolumus eluting stents than in paxlitaxel eluting
stents.1
The mechanisms of action of the two drugs merit
some consideration. Sirolimus, a macrocyclic lactone,
inhibits mammalian target of rapamycin (mTOR)
thereby blocking cell division by interfering at the
transition from G1 to S phase.28 People with diabetes
show a breakdown in the phosphatidylinositol 3 kinase
insulin signal transduction pathway, wheremTORhas
an important role,29 and this has been thought to limit
the effectiveness of sirolimus in people with diabetes
mellitus. Paclitaxel, which affects cell replication by
stabilising microtubules, does not seem to be influ-
enced by insulin resistance andwas therefore hypothe-
sised tobe superior to sirolimus inpeoplewithdiabetes.
The present study does not support these speculations:
although paclitaxel eluting stents tended to reduce the
risk of target lesion revascularisation more strongly in
people with diabetes than in people without diabetes,
sirolimus eluting stents were superior to paclitaxel
eluting stents in reducing the riskof revascularisation in
people both with and without diabetes.
Rapid technological developments led to novel,
second generation drug eluting stents using different
antiproliferative substances, absorbablepolymersused
as drug carriers, and fully bioabsorbable stent systems.
Although the short term results for effectiveness of
thesenewgenerationdevicesare encouraging,30-32 their
long term safety profile in people with and without
diabetes is still ill defined. An expansion of the present
network meta-analysis will be required as soon as
longer term follow-up data become available for these
novel stent systems.
Conclusion
In trials with a duration of dual antiplatelet therapy of
six months or longer drug eluting stents were safe and
effective in people with and without diabetes. It seems
prudent to adhere to a minimal duration of dual
antiplatelet therapy of six months in patients under-
going implantation of a drug eluting coronary stent.
The potential benefits of a longer duration of therapy
need to be balanced against potential risks, such as
clinically relevant bleeding. The optimal duration can
only be determined in adequately powered large scale
randomised controlled trials.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
People with diabetes are at an increased risk for coronary heart disease and have more
restenoses after the implantation of coronary stents
Ameta-analysis suggested a strongly increased riskof death associatedwith sirolimuseluting
stents compared with bare metal stents in people with diabetes
WHAT THIS STUDY ADDS
Reported increases in the riskofdeathassociatedwithdrugelutingstents comparedwithbare
metal stents inpeoplewithdiabeteswereprobablydue todualantiplatelet therapy lasting less
than six months in early trials
In trialswithdualantiplatelet therapy for sixmonthsor longerdrugelutingstentsweresafeand
effective in people both with and without diabetes
Inclinicalpractice itseemsprudent toadhere toaminimaldurationofdualantiplatelet therapy
of six months in all patients undergoing implantation of a drug eluting coronary stent
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